



File No.: PATENT
94-9C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kenneth Kaushansky
Serial No.: 08/347,748 Group Art Unit:
Filed: December 1, 1994 Examiner:
For: METHODS FOR STIMULATING ERYTHROPOIESIS USING
HEMATOPOIETIC PROTEINS

AMENDMENT FEE TRANSMITTAL

Hon. Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below

CLAIMS AS AMENDED


	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	30	30	0	\$22.00	\$000.00
Independent	7	7	0	\$76.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$240.00	\$000.00
Total					\$000.00

Please charge any additional fees to ZymoGentics, Inc.,
Deposit Account No. 26-0290. A duplicate of this sheet is
enclosed.

Respectfully submitted,
Kenneth Kaushansky

Deborah A. Sawislak

Deborah A. Sawislak
Registration No. 37,438



0300

025 1

6-000
1-6-95

A/N

I hereby certify that this correspondence is being PATENT deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date

12.16.94

Deborah A. Sawislak

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kenneth Kaushansky

Serial No. : 08/347,748

Filed : December 1, 1994

For : METHODS FOR STIMULATING ERYTHROPOIESIS USING
HEMATOPOIETIC PROTEINS

Examiner :

Art Unit :

Docket No.: 94-9C2

Date : December 16, 1994

Commissioner of Patents and Trademarks
Washington, D.C. 20231Preliminary Amendment

Sir:

In the Specification:

Please include Figure 1 and Figure 2 in specification after The Abstract of the Disclosure.

REMARKS

Consideration of the application in view of the above amendment and following remarks is requested.

Applicant respectfully submits that the amendment to the specification does not constitute new matter. This application is a continuation of U. S. Patent Application